AstraZeneca Pharma receives marketing approval for Benralizumab in India
AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) for an additional indication.
Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
The receipt of this permission paves way for the marketing of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
7 hours ago
- New Indian Express
Medical representatives banned from visiting doctors in central government hospitals
NEW DELHI: The centre has directed central government hospitals, including Safdarjung and Dr RML Hospitals, to not allow medical representatives inside the hospital premises. This is not the first time the centre has issued such a stern message barring pharma companies' from influencing doctors'. In an order issued on May 28, the Directorate General of Health Services (DGHS), Dr Sunita Sharma, said, 'This is in reference to the earlier instructions regarding not permitting entry of medical representatives in hospital premises. In this regard, it is once again instructed that the medical representatives should not be permitted in the hospital premises. The head of the institutions shall give necessary strict directions in the matter to all officials,' said the order, which was marked to Medical Superintendents of Safdarjung Hospital and Dr. Ram Manohar Lohia Hospital, and Directors of Lady Hardinge Medical College and Associated Hospitals and Rural Health Training Centre, Najafgarh. 'Medical representatives may be requested to share recent advances regarding any treatment/investigation/procedure by email or other digital media,' the notice clarified. 'It is requested to take necessary action in the matter and an action taken report may be furnished to this Directorate,' the order further added. Reacting to the order, RTI activist and ophthalmologist, Dr K V Babu said, 'Though I support not allowing medical representatives during working hours, blanket ban on entry is not a welcome decision." Dr Babu highlighted the issue of 30 doctors, who travelled to foreign countries, with the funding of a pharma company to the tune of Rs. 1.9 crore. He said he had filed an RTI on the issue. The DoP in its order, dated December 23, told him that they will share the details of the doctors. But, he said, "they are still sitting over it even after five months. No action against the pharma company was also taken despite the UCPMP code being in place.' The Department of Pharmaceuticals (DoP) last year notified a new code that prohibits pharma companies from offering gifts and travel facilities to healthcare professionals or their family members. The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 also bans supply of free samples to those who are not qualified to prescribe such a product. However, the Alliance of Doctors for Ethical Healthcare (ADEH) has been demanding that the UCPMP be made mandatory to bring fairness in marketing of the drugs as the industry has failed to comply with the code on a voluntary basis.
&w=3840&q=100)
Business Standard
17 hours ago
- Business Standard
Biocon share price pops 2% on CDSCO nod for diabetes drug; key details here
Biocon share price: Bengaluru-based biopharmaceutical company Biocon shares were in demand in a weak market on Tuesday, June 3, 2025, with the stock rising up to 1.85 per cent to hit an intraday high of 340.25 per share. However, at 11:00 AM, Biocon share price was trading 0.49 per cent higher at 335.70 per share. What is the reason behind the uptick in Biocon share price? Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug. The company received approval from the Central Drugs Standard Control Organisation (CDSCO) for its Liraglutide drug substance, while its wholly owned subsidiary, Biocon Pharma, secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). Liraglutide is a synthetic analog of the GLP-1 peptide and is administered as a once-daily injection. It is a generic version of Victoza and is indicated for the treatment of Type 2 Diabetes Mellitus in adults, adolescents, and children aged 10 years and older, as an adjunct to diet and exercise. The original formulation was approved in the EU in 2009 and in the US in 2010. The approvals were granted under the CDSCO's recently introduced 101 route, which recognises approvals from established global regulatory authorities, streamlining the approval process in India. Siddharth Mittal, chief executive officer and managing director, Biocon, said: 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest numbers of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India'' 'With GLP-1 therapies projected to be a substantive future growth driver for Biocon, the Company remains committed to reinforcing its position as a key player in this area,' Biocon said, in a statement. Biocon Q4 results Biocon reported a strong financial performance for the fourth quarter of FY25, with consolidated net profit surging 153 per cent year-on-year (Y-o-Y) to ₹344 crore, up from ₹136 crore in the same quarter last year. Profit before tax (PBT) rose 53 per cent Y-o-Y to ₹487 crore. The company's Board also approved plans to raise up to ₹4,500 crore through various funding options, including qualified institutional placement (QIP), rights issue, or other permissible methods. The robust growth was driven by solid performance across its generics, biologics, and research services segments. Total consolidated revenue for the quarter stood at ₹4,454 crore, compared to ₹3,966 crore in Q4 FY24. Ebitda rose 16 per cent to ₹1,115 crore, with the margin maintained at 25 per cent. READ MORE About Biocon Biocon is a global biopharmaceutical company focused on developing and supplying affordable therapies for chronic diseases such as diabetes, cancer, and autoimmune disorders. The company manufactures and markets novel biologics, biosimilars, complex small molecule APIs, and generic formulations across India, the US, Europe, and other key markets. It is also advancing a pipeline of novel immunotherapy assets.
India Gazette
2 days ago
- India Gazette
Uttarakhand: Valley of Flowers opens for tourists on June 1
Dehradun (Uttarakhand) [India], June 1 (ANI): The world-renowned Valley of Flowers in the Chamoli district of Uttarakhand welcomed tourists on Sunday. On its first day, the forest department staff welcomed visitors at the main gate, where 62 tourists had registered so far in June. This valley features over 300 species of Himalayan flowers. The Valley of Flowers, a UNESCO World Heritage Site, is famous for its over 500 plant species. It is open for tourists every year from June to October. The valley is situated in the Garhwal Himalayas, next to Nanda Devi National Park, and is known for its serene, picturesque beauty. The chief minister announced on Saturday that the Uttarakhand government is ready to take a step toward scientific, safe, and environmentally responsible medicine disposal in the state. Chief Minister Pushkar Singh Dhami has started work towards implementing the guidelines issued by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, in the state. A release said this decision is not just an administrative process but a transformative initiative to make Uttarakhand a model state of a 'green health system' across the country. Health Secretary and Commissioner of the FDA, Dr. R. Rajesh Kumar, said that till now, there has been a lack of a clear and consistent system for the disposal of expired and unused medicines.'This challenge becomes more serious in an environmentally sensitive state like Uttarakhand. Now we are moving towards controlling it under a well-planned system,' Kumar said. He informed that in these guidelines, the process has been decided keeping in mind every stage of the life cycle of medicines from production to consumption and then proper disposal. Kumar further said that under the 'Healthy Citizen, Clean Uttarakhand' mission announced by the Chief Minister, this initiative will take the state towards a green and sustainable healthcare model. With this decision, the possibility of establishing the state as a leading state in the field of environmental responsibility and health security at the national and international levels has also become stronger. Only the active participation of all the parties involved in this entire process, policymakers, business organisations and common citizens, can make this mission successful. Uttarakhand is moving towards becoming an example in this direction. Dr. R. Rajesh Kumar informed that as per the plan of the Health Department, 'Drug Take-Back Sites' will be set up in a phased manner in urban, semi-urban and hilly areas of Uttarakhand. Here, common citizens will be able to deposit unused, expired or spoiled medicines lying in their homes. Medicines from these centres will be collected scientifically and disposed of in specially approved processing units. (ANI)
